Magnetar Financial’s Eucrates Biomedical Acquisition Corp. Unit EUCRU Stock Holding History

Magnetar Financial’s Portfolio EUCRU Stock Details EUCRU Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-392,001	Closed	-$3.93M	–	1799
2022 Q2	$3.93M	Sell	392,001 -57,999	-13%	-$576K	0.04%	376
2022 Q1	$4.45M	Sell	450,000 -657	-0.1%	-$6.52K	0.05%	396
2021 Q4	$4.5M	Sell	450,657 -4,000	-0.9%	-$40.2K	0.05%	411
2021 Q3	$4.53M	Hold	454,657	–	–	0.05%	393
2021 Q2	$4.63M	Buy	454,657 +4,657	+1%	+$46.8K	0.04%	394
2021 Q1	$4.54M	Sell	450,000 -50,000	-10%	-$533K	0.04%	365
2020 Q4	$5.25M	Buy	+500,000	New	+$5.08M	0.07%	242

Other funds holding EUCRU

Verition Fund Management Greenwich, Connecticut $19.7B AUM 39.39% 1-Year Est. Return

SCM

Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return

Wealthspring Capital West Harrison, New York $448M AUM 8.38% 1-Year Est. Return

CIM

Cowen Investment Management New York $12M AUM 1.47% 1-Year Est. Return

HIM

HGC Investment Management Toronto, Ontario, Canada $507M AUM 6.15% 1-Year Est. Return

SIA

Schechter Investment Advisors Birmingham, Michigan $1.21B AUM 8.73% 1-Year Est. Return

RCM

Rivernorth Capital Management West Palm Beach, Florida $2.1B AUM 2.15% 1-Year Est. Return

HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return

GCL

Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

WAM

Wolverine Asset Management Chicago, Illinois $11.4B AUM 5.65% 1-Year Est. Return

Magnetar Financial's EUCRU Position: Q3 2022 in Review

Magnetar Financial sold out of Eucrates Biomedical Acquisition Corp. Unit (EUCRU) in Q3 2022, closing a stake of 392,001 shares — an estimated $3.93M sold.

Magnetar Financial first reported a position in EUCRU in Q4 2020 and held it in 7 quarters. The position peaked at $5.25M in Q4 2020. 13 funds tracked by Wall St. Rank hold EUCRU as of Q3 2022.

Magnetar Financial reported no remaining Eucrates Biomedical Acquisition Corp. Unit position as of Q3 2022 after selling out during the quarter.
Magnetar Financial sold 392,001 Eucrates Biomedical Acquisition Corp. Unit shares in Q3 2022, an estimated $3.93M.
Magnetar Financial first reported a position in Eucrates Biomedical Acquisition Corp. Unit in Q4 2020 and held it in 7 quarters.
Magnetar Financial's Eucrates Biomedical Acquisition Corp. Unit position peaked at $5.25M in Q4 2020.
13 funds tracked by Wall St. Rank held Eucrates Biomedical Acquisition Corp. Unit as of Q3 2022.

Based on Magnetar Financial's 13F filing for Q3 2022, filed 14 Nov 2022.